{"schema_version":"secwatch.filing_event.v1","accession":"0001610618-24-000043","form_type":"8-K","ticker":null,"cik":"0001610618","company_name":"Cidara Therapeutics, Inc.","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.245460+00:00","generated_at":"2026-06-03T13:59:22.215513+00:00","sec_items":["2.02","3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cidara reports FY2023 net loss $22.9M; effects 1-for-20 reverse stock split","bullets":["Net loss $22.9M in FY2023 ($33.6M in 2022); revenue $63.9M. Cash $35.8M at Dec 31, 2023.","1-for-20 reverse stock split effective April 23, 2024; shares begin trading split-adjusted April 24.","REZZAYO approved in EU and UK; Cidara received $11.1M and $2.8M milestone payments.","IND for lead oncology DFC CBO421 expected mid-2024; Phase 3 ReSTORE China data expected Q2 2024.","Financial results restated to correct understated accrued liabilities and operating expenses from indirect taxes."],"urls":{"canonical":"https://secwatch.observer/filing/0001610618-24-000043","json":"https://secwatch.observer/filing/0001610618-24-000043.json","markdown":"https://secwatch.observer/filing/0001610618-24-000043.md","text":"https://secwatch.observer/filing/0001610618-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/cdtx-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:59:22.215513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46714d0ac1f4346372f6edf947fb6ec2e46577d8","claim":"Cidara Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $17.6 million and $63.9 million.","evidence_excerpt":"a Top Workplace by The San Diego Union-Tribune for the sixth year, ranking among the top 100 companies. Fourth Quarter and Full Year 2023 Financial Results • Revenue totaled $17.6 million and $63.9 million for the three months and full year ended December 31, 2023, respectively, compared with $10.2 million and $64.4 million for the same periods in 2022. Revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$17.6 million and $63.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4972c2ca7c315a00362c3ee8482cbf72cdbf024a","claim":"Cidara Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-20 reverse stock split and reduce authorized shares to 20,000,000 (effective 2024-04-23).","evidence_excerpt":"On April 22, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-20 reverse stock split of the Company’s outstanding common stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-23"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}